研究者業績
基本情報
研究キーワード
1経歴
1-
2025年4月 - 現在
学歴
2-
2009年 - 2013年
-
1989年4月 - 1993年3月
論文
21-
Fujita Med J 11(3) 105-110 2025年8月 査読有り
-
Journal of Pharmaceutical Health Care and Sciences 10(1) 2024年10月31日 査読有り筆頭著者Abstract Background This study aimed to clarify the effectiveness of nutrition support team (NST) facilities for preventing central line-associated bloodstream infection (CLABSI). Methods We retrospectively analyzed the incidence of CLABSI as well as the presence or absence of additional medical fees for NST activity between 2019 and 2021, including the period before and after the COVID-19 pandemic. Subsequently, we performed between-group comparisons of the CLABSI incidence. CLABSI rates were compared based on cumulative per 1000 catheter uses during the relevant period. Results Among 47 facilities that were registered for participation, there were 34 and 13 facilities with and without additional medical fees for NST activity (NST and non-NST groups, respectively). The CLABSI incidence rate was significantly lower in the NST group 0.96 [0.28–1.73] than in the non-NST group 1.25 [075–6.10] (p < 0.05). Before the pandemic, the NST group had a lower CLABSI rate per 1000 catheter uses than the non-NST group 2019: 0.70 [0.12–1.26] vs 2.10 [0.62–5.97]. During the pandemic, the CLABSI incidence showed no significant between-group difference 2020: 0.99 [0.51–1.61] vs 1.01 [0.80–4.16]; 2021: 1.24 [0.44–2.35] vs 1.96 [1.23–5.31]; however, the CLABSI rates in the NST group remained low. Conclusion During the COVID-19 pandemic, the incidence of CLABSI was lower in the NST group than in the non-NST group, indicating the effectiveness of NST in preventing the occurrence of CLABSI.
-
In Vivo 38(6) 3041-3049 2024年10月29日 査読有り筆頭著者
-
Medicine 103(26) e38675-e38675 2024年6月28日 査読有りIntroduction: Healthy eating and weight control are recommended for cancer survivors; however, dietary interventions are not routinely offered to them. This study aimed to assess the effects of dietary interventions on survival, nutritional status, morbidity, dietary changes, health-related quality of life (QOL), and clinical measures in cancer survivors. Methods: Searches were conducted from October 1, 2018 to November 21, 2011 in the Medline, EMBASE, CENTRAL, Emcare, and DARE electronic databases. We included randomized controlled trials (RCTs) that involved individuals diagnosed with cancer, excluding conference abstracts, case studies, other reviews, and meta-analyses, and screened the articles. Results: Eight studies were included in this meta-analysis. We observed significant improvements in QOL and clinical data in 3 of 6 studies and in one study, respectively, significant weight loss on anthropometry in 2 of 5 studies, and dietary improvement in 4 of 5 studies of adult cancer survivors. However, we did not observe any benefits of dietary intervention for cancer survivors with undernutrition. Discussion: Dietary interventions for adult cancer survivors might contribute to improving their nutritional status; however, further clarification requires a study that standardizes the intervention method. Furthermore, RCTs are required to determine the effects on cancer survivors with undernutrition.
MISC
104-
日本臨床検査自動化学会会誌 37(1) 99-104 2012年1月1日
-
日本緩和医療学会学術大会プログラム・抄録集 16th 414 2011年6月27日
-
Palliat Care Res (Web) 6(1) 316-323 (J-STAGE)-323 2011年がん患者の浮腫には, 悪液質や低タンパク血症, リンパ浮腫などがあるが, 腫瘍に起因するネフローゼ症候群(NS)がその原因となることもある. これら浮腫はQOLを低下させるだけでなく, 的確に診断・治療しなければ死期を早めてしまう危険もある. 前医にて子宮体がん再発によるリンパ浮腫と診断され, 当院にてNSの治療によりQOLが著明に改善した1例を経験したので報告する. 65歳, 女性, 子宮体がん再発, 肺・脳転移. 在宅療養中, 状態の悪化にて緊急入院. 両下肢に著明な浮腫を認め, 検査成績でTP 5.0 g/dl, ALB 1.3 g/dl, T-Chol 369 mg/dl, タンパク尿(3+)にてNSの診断基準を満たした. ALB製剤の静脈投与にて, 循環動態を安定させ, ステロイド・免疫抑制剤を投与した結果, 全身状態, 浮腫も改善. その後はNSの軽快・増悪を繰り返し, 腫瘍が進展し入院81日目に播種性血管内凝固, 多臓器不全をきたし死亡. 悪性腫瘍が起因となるNSはまれではない. しかし, 肺がんや消化器系がんが多く, 子宮体がんはまれである. 悪性腫瘍の終末期の浮腫の原因としてNSも念頭に入れて治療を行う必要がある. Palliat Care Res 2011; 6(1): 316-323
-
Nutr Care 3(4) 355-357 2010年7月10日
-
外科と代謝・栄養 43(4) 51-60 2009年8月15日
-
生物試料分析 31(3) 204-214 2008年6月30日
共同研究・競争的資金等の研究課題
1-
日本学術振興会 科学研究費助成事業 2016年4月 - 2019年3月